Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "NextGen-O2k Exploitation"

From Bioblast
Line 26: Line 26:
<br/>
<br/>
<gallery mode=default perrow=4 widths="350px" heights="300px">
<gallery mode=default perrow=4 widths="350px" heights="300px">
File:Analytica China 2020 2.jpg|The [[CN Beijing Huawei]] team representing Oroboros Instruments at the [[Analytica China 2020 Shanghai CN|Analytica China 2020 Event]] November 2020
File:Analytica China 2020 2.jpg|The [[CN Beijing Huawei]] team representing Oroboros Instruments at [[Analytica China 2020 Shanghai CN|Analytica China 2020]]. November 2020
File:Timi in Linz Aug 2020.jpg|[[Komlodi Timea|Timea Komlodi, PhD.]] at an on-site visit in Linz August 2020
File:Timi in Linz Aug 2020.jpg|[[Komlodi Timea|Timea Komlodi, PhD.]] at an on-site visit in Linz, August 2020


File:JP Onsite.jpg|[[Cardoso Luiza HD|Luiza Cardoza, PhD.]] at an on-site visit in Japan February 2020
File:JP Onsite.jpg|[[Cardoso Luiza HD|Luiza Cardoza, PhD.]] at an on-site visit in Japan, February 2020


File:ASMRM2021.JPG|Snapshot of the [[ASMRM & J-mit 2019 Fukuoka JP|J-Mit and ASMRM 2019]]
File:ASMRM2021.JPG|Snapshot of the [[ASMRM & J-mit 2019 Fukuoka JP|J-Mit and ASMRM 2019]]


File:ASMRM & J-mit 2019 Fukuoka JP.jpeg|The Oroboros booth at the [[ASMRM & J-mit 2019 Fukuoka JP|ASMRM & J-mit October 2019]]
File:ASMRM & J-mit 2019 Fukuoka JP.jpeg|The Oroboros booth at the [[ASMRM & J-mit 2019 Fukuoka JP|ASMRM & J-mit]], October 2019
File:ORODM1A.jpg|The first [[OroDM01 Innsbruck AT|Distributor Meeting]] July 2019
File:ORODM1A.jpg|The first [[OroDM01 Innsbruck AT|Distributor Meeting]], July 2019


|-
|-
</gallery>
</gallery>
== Links and references ==

Revision as of 10:43, 6 May 2021

Template:MitoFit highlights page name

NextGen-O2k

The revolutionary all-in-one instrument to conquer mitochondrial disease.



WP4: Exploitation



Abstract

Preparation for a successful market launch of the NextGen-O2k.

Achievements

Project Year 1: During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures.
Project Year 2: Year 2 was focused on ensuring processes were in place to deliver high quality and customer satisfaction. This included creating a quality policy statement as well as carrying out a customer satisfaction survey. Our Distributor Relations Dragon, Feiyuan Zhang, continued to work closely with our distributors keeping them abreast of progress and gaining valuable feedback.

Progress and next steps

See » Track record